Andrew B Herr

US Patent:

20100317536, Dec 16, 2010

Filed:

Mar 28, 2007

Appl. No.:

12/294581

Inventors:

Andrew B. Herr - Cincinnati OH, US
Katsunori Horii - Hyogo, JP

Assignee:

University of Cincinnati - Cincinnati OH

International Classification:

C40B 30/02
G01N 33/50
G01N 33/53
C07K 14/705
G06G 7/48

US Classification:

506 8, 436 87, 435 78, 530395, 703 11

Abstract:

A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.

US Patent:

20110189260, Aug 4, 2011

Filed:

May 29, 2009

Appl. No.:

12/994921

Inventors:

Andrew B. Herr - Cincinnati OH, US
Deborah Gail Conrady - Cincinnati OH, US
Cristin C. Brescia - Canton OH, US
Stefanie L. Ward - Cincinnati OH, US

Assignee:

UNIVERSITY OF CINCINNATI - Cincinnati OH

International Classification:

A01N 37/12
A01N 43/42
A01N 33/02
A61K 9/00
A61K 31/195
A61K 31/4375
A61K 31/13
A01P 1/00
A61P 31/04

US Classification:

424447, 514566, 514292, 514638, 424 54

Abstract:

A method is provided for inhibiting formation of a biofilm of bacteria, the method including contacting the bacteria with an effective amount of at least one zinc chelator, wherein the bacteria contain at least one zinc adhesion module, whereby formation of the biofilm is inhibited. A method for inhibiting biofilm formation on a device and a topical pharmaceutical composition for the inhibition of biofilm formation are also provided.

US Patent:

20120135880, May 31, 2012

Filed:

Nov 28, 2011

Appl. No.:

13/304942

Inventors:

Andrew B. Herr - Cincinnati OH, US
Katsunori Horii - Hyogo, JP

International Classification:

C40B 30/04
G06G 7/60
G01N 33/53

US Classification:

506 9, 435 71, 703 11

Abstract:

A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.

US Patent:

20220249437, Aug 11, 2022

Filed:

Jul 9, 2020

Appl. No.:

17/597515

Inventors:

- Cincinnati OH, US
Andrew Herr - Cincinnati OH, US
Suhas G. Kallapur - Cincinnati OH, US
Jarek Meller - Cincinnati OH, US
Alexander Thorman - Cincinnati OH, US

International Classification:

A61K 31/382
A61K 31/353
A61K 47/69

Abstract:

The disclosure provides compounds of Formula I and their use in methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

US Patent:

20230131243, Apr 27, 2023

Filed:

Dec 19, 2022

Appl. No.:

18/083617

Inventors:

- Cincinnati OH, US
Andrew Herr - Cincinnati OH, US
Suhas G. Kallapur - Cincinnati OH, US
Jarek Meller - Cincinnati OH, US
Alexander Thorman - Cincinnati OH, US

Assignee:

CHILDREN'S HOSPITAL MEDICAL CENTER - Cincinnati OH

International Classification:

A61K 31/713
A61K 31/655
A61K 31/7105
C12N 15/113
C07K 16/18

Abstract:

The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

US Patent:

20210371519, Dec 2, 2021

Filed:

Sep 20, 2019

Appl. No.:

17/277071

Inventors:

- Cincinnati OH, US
- Kiel, DE
Crystal Potter - Fairfield OH, US
Elizabeth Angerman - Fort Thomas KY, US
Andrew Herr - Cincinnati OH, US
Matthias Peipp - Hamburg, DE

International Classification:

C07K 16/28
A61P 37/08

Abstract:

A monovalent monoclonal antibody is provided, the antibody including one light chain, one heavy chain, and one truncated heavy chain, wherein the truncated heavy chain lacks a variable domain and a CH1 domain and wherein the antibody specifically binds an epitope of FcεRIα. Also provided are methods of desensitizing a subject to an allergen, methods of treating an allergy, and methods of preventing an allergic reaction in a subject having an allergy.

US Patent:

20210113604, Apr 22, 2021

Filed:

Jan 14, 2019

Appl. No.:

15/733346

Inventors:

- Cincinnati OH, US
Andrew Herr - Cincinnati OH, US
Suhas G. Kallapur - Cincinnati OH, US
Jarek Meller - Cincinnati OH, US
Alexander Thorman - Cincinnati OH, US

International Classification:

A61K 31/713
A61K 31/7105
C12N 15/113
C07K 16/18

Abstract:

The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

US Patent:

20140308326, Oct 16, 2014

Filed:

Apr 16, 2014

Appl. No.:

14/254362

Inventors:

Andrew B. HERR - Cincinnati OH, US
Stephan DAVIS - Coral Gables FL, US
Gary YOUNG - Coral Gables FL, US

Assignee:

UNIVERSITY OF CINCINNATI - Cincinnati OH

International Classification:

A01N 25/08
A61K 47/12
A01N 43/16
A61K 31/7036

US Classification:

424404, 514 40

Abstract:

Pharmaceutical compositions comprising an aminoglycosidic antibiotic and at least one zinc-chelating agent in a specified concentration, and methods of inhibiting bacterial colonization, biofilm formation and if treating bacterial infections utilizing the compositions are provided. Topical formulations suitable for wound care, and surface-applicable formulations suitable for medical, industrial and household disinfecting needs are also described.